Gastroenterology Month in Review: January 2024

Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.

Related Keywords

Evan Dellon ,Dupilumab Dupixent ,Julie Khlevner ,Drug Administration ,University Of North Carolina Chapel Hill ,Contemporary Pediatric ,Esophageal Diseases ,North Carolina Chapel Hill ,Pediatric Gastrointestinal Motility Center ,Columbia University Medical Center ,Ibd ,Inflammatory Bowel Disease ,Constipation ,Linaclotide ,Eosinophilic Esophagitis ,Dupilumab ,Bustekinumab ,Ulcerative Colitis ,